Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 85NIH 69NETWORK 30INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Neoplasms 3214Carcinoma, Non-Small-Cell Lung 2727Breast Neoplasms 2550Colorectal Neoplasms 1461Prostatic Neoplasms 1307Neoplasm Metastasis 1300Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 944Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 832Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 472Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 435Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

Granulocyte Colony-Stimulating Factor 1Filgrastim 1Cytarabine 1Clofarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myelomonocytic, Acute × Clear all
NCT04803929 2021-03-23

Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)

Carbiogene Therapeutics Co. Ltd.

Phase EARLY_PHASE1 Unknown
25 enrolled
Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myelomonocytic, Acute

NCT01031368 2019-03-01

Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia

Nohla Therapeutics, Inc.

Phase 1 Completed
29 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute

NCT00363974 2009-12-01

Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML

Aegera Therapeutics

Phase 1/2 Completed
54 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡